




The relative strengths and weaknesses of Spero Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Spero Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 136% points. The greatest weakness of Spero Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 359%, being 107% points above the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	92,059
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,157
Liabilities, Non-Current	0
Other Assets	256
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	365
Other Net Income	3,823
Other Revenues	0
Property and Equipment	1,164
Research and Development	32,869
Selling, General and Administrative Expense	10,840

Output Variable	Value in 1000 USD
Assets	93,479
Liabilities	8,522
Expenses	43,709
Revenues	0
Stockholders Equity	84,957
Net Income	-39,886
Comprehensive Net Income	-39,886
BaseVar	74,766
ECR before Limited Liability	285%
Economic Capital Ratio	359%